All the Active Ingredient Drugs
EGFR Inhibitor, Monoclonal Antibody. Cetuximab 5 mg/ml. VIAL (I.V. infus.): 20 ml, 100 ml. Initial: 400 mg/m2, foll. by 1 x wkly. dose of 250 mg/m2. See lit.
Tmt. of pts. with (EGFR)-expressing, RAS
wild-type metast. colorectal canc. in
comb. with irinotecan-based chemot., in
1st -line in comb. with FOLFOX, as a single
agent in pts. who have failed oxaliplatin and irinotecan- based ther. and who
are intoler. to irinotecan. Tmt. of pts. with
squamous cell canc. of the head and neck
(SCCHN), in comb. with rad. ther. for
local. advanced dis., in comb. with
platinum-based chemo. for recur. and/
or metast. dis., as a single agent after fail.
of platinum-based chemo. for recur.
and/or metast. dis.
C/I: Severe hypersens, The comb. with
oxaliplatin-cont. chemot. is contraindic.
for pts. with mutant RAS metast.
colorectal canc. (mCRC) or for whom
RAS mCRC status is unknown.
Contraind. for concom. used chemot.
agents or rad. ther. must be
considered before init. of comb. tmt.
